Brief: Bicycle Therapeutics Announces FDA Fast Track Designation For Bt8009
04/01/2023 12:43
Jan 4 (Reuters) - Bicycle Therapeutics PLC BCYC.O :
* BICYCLE THERAPEUTICS ANNOUNCES FDA FAST TRACK DESIGNATION
GRANTED TO BT8009 FOR THE TREATMENT OF ADULT PATIENTS WITH
PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL
CANCER
Source text for Eikon: ID:nBw3HwQf2a
Further company coverage: BCYC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bicycle Therapeutics
See all newsBicycle Therapeutics Q1 revenue drops after partnership terminations
Brief: Bicycle Therapeutics Announces Oral And Poster Presentations At The Aacr Annual Meeting 2026
UK's Bicycle Therapeutics Q4 revenue jumps, proposes 30% workforce reduction
Brief: Bicycle Therapeutics Says Travis Thompson Appointed As CFO, Succeeds Alethia Young
Bicycle Therapeutics Q3 net loss widens as R&D costs rise